CliffBio

Regeneron Pharmaceuticals

Patent cliffs & loss of exclusivity

A biopharmaceutical company developing, manufacturing and commercializing medicines for treating serious medical conditions.

Company

AngelList URLhttps://angel.co/regeneron-pharmaceuticals
CAGE Code544P9
Legal NameRegeneron Pharmaceuticals, Inc.
Company Operating StatusActive
Contact Page URLhttps://www.regeneron.com/contact
Crunchbase URLhttps://www.crunchbase.com/organization/regeneron-pharmaceuticals
Facebook URLhttps://www.facebook.com/Regeneron/
Full Address777 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591 UNITED STATES

17 upcoming patent cliffs

DrugIngredientTypeCliff
  1. EyleaafliberceptBiologicMay 2024
  2. PraluentalirocumabBiologicJul 2027
  3. PraluentalirocumabBiologicJul 2027
  4. DupixentdupilumabBiologicMar 2029
  5. EyleaafliberceptBiologicAug 2030
  6. Libtayocemiplimab-rwlcBiologicSep 2030
  7. DupixentdupilumabBiologicOct 2030
  8. DupixentdupilumabBiologicJun 2032
  9. Inmazebatoltivimab, maftivimab, and odesivimab-ebgnBiologicOct 2032
  10. Evkeezaevinacumab-dgnbBiologicFeb 2033
  11. Evkeezaevinacumab-dgnbBiologicFeb 2033
  12. DupixentdupilumabBiologicJun 2033
  13. Inmazebatoltivimab, maftivimab, and odesivimab-ebgnBiologicSep 2033
  14. Veopozpozelimab-bbfgBiologicAug 2035
  15. Eylea HDafliberceptBiologicAug 2035
  16. Lynozyficlinvoseltamab-gcptBiologicJul 2037
  17. Lynozyficlinvoseltamab-gcptBiologicJul 2037
  18. OTARMENIlunsotogene parvec-cwhaBiologicApr 2038

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Regeneron Pharmaceuticals — patent cliffs & loss of exclusivity | CliffBio